Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study

Author(s): Bhuvanachandra Pasupuleti, Vamshikrishna Gone*, Ravali Baddam, Raj Kumar Venisetty and Om Prakash Prasad

Volume 21, Issue 2, 2020

Page: [126 - 131] Pages: 6

DOI: 10.2174/1389200221666200218121050

Price: $65

Abstract

Background: Clobazam (CLBZ) metabolized primarily by Cytochrome P-450 isoenzyme CYP3A4 than with CYP2C19, Whereas Levetiracetam (LEV) is metabolized by hydrolysis of the acetamide group. Few CYP enzymes are inhibited by Proton Pump Inhibitors (PPIs) Pantoprazole, Esomeprazole, and Rabeprazole in different extents that could affect drug concentrations in blood. The aim of the present study was to evaluate the effect of these PPIs on the plasma concentrations of LEV and CLBZ.

Methods: Blood samples from 542 patients were included out of which 343 were male and 199 were female patients and were categorized as control and test. Plasma samples analyzed using an HPLC-UV method. Plasma concentrations were measured and compared to those treated and those not treated with PPIs. One way ANOVA and games Howell post hoc test used by SPSS 20 software.

Results: CLBZ concentrations were significantly 10 folds higher in patients treated with Pantoprazole (P=0.000) and 07 folds higher in patients treated with Esmoprazole and Rabeprazole (P=0.00). Whereas plasma concentration of LEV control group has no statistical and significant difference when compared to pantoprazole (P=0.546) and with rabeprazole and esomeprazole was P=0.999.

Conclusion: The effect of comedication with PPIs on the plasma concentration of clobazam is more pronounced for pantoprazole to a greater extent when compared to esomeprazole and rabeprazole. When pantoprazole is used in combination with clobazam, dose reduction of clobazam should be considered, or significance of PPIs is seen to avoid adverse effects.

Keywords: Levetiracetam, clobazam, proton pump inhibitors, drug interactions, CYP2C19, CYP3A4.

« Previous Next »
Graphical Abstract

[1]
American Society of Health-System Pharmacists; Drug Information,Clobazam - National Library of Medicine, Bethesda, MD. 2016, 2295.https://toxnet.nlm.nih.gov (Accessed February 7, 2019)
[2]
Andersson, T.; Miners, J.O.; Veronese, M.E.; Tassaneeyakul, W.; Tassaneeyakul, W.; Meyer, U.A.; Birkett, D.J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol., 1993, 36(6), 521-530.
[http://dx.doi.org/10.1111/j.1365-2125.1993.tb00410.x] [PMID: 12959268]
[3]
Aylett, S.E.; Cross, H.; Berry, D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Dev. Med. Child Neurol., 2006, 48(7), 612-615.
[http://dx.doi.org/10.1017/S0012162206001289] [PMID: 16780634]
[4]
Bremer, S.C.B.; Reinhardt, L.; Sobotta, M.; Hasselluhn, M.C.; Lorf, T.; Ellenrieder, V.; Schwörer, H. Pantoprazole Does not affect serum trough levels of tacrolimus and everolimus in liver transplant recipients. Front. Med. (Lausanne), 2018, 5, 320.
[http://dx.doi.org/10.3389/fmed.2018.00320] [PMID: 30510930]
[5]
Crepeau, A.Z.; Treiman, D.M. Levetiracetam: a comprehensive review. Expert Rev. Neurother., 2010, 10(2), 159-171.
[http://dx.doi.org/10.1586/ern.10.3] [PMID: 20136375]
[6]
Dasgupta, A. Introduction to Therapeutic drug monitoring, 1st ed; Academic Press: USA, 2012.
[http://dx.doi.org/10.1016/B978-0-12-385467-4.00001-4]
[7]
DailyMed; Current Medication Information for Onfi (Clobazam) Tablet,Onfi (Clobazam) Suspension, U.S national library of medicine, 2016.https://dailymed.nlm.nih.gov (Accessed February 20, 2019)
[8]
de Wildt, S.N.; Kearns, G.L.; Leeder, J.S.; van den Anker, J.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet., 1999, 37(6), 485-505.
[http://dx.doi.org/10.2165/00003088-199937060-00004] [PMID: 10628899]
[9]
Epilepsy foundation; Levetiracetam. 8301 Professional Place West,Suite 230, Landover, MD 20785 https://www.epilepsy.com (Accessed February 20, 2019)
[10]
Epilepsy foundation; Clobazam. 8301 Professional Place West, Suite 230, Landover, MD 20785 https://www.epilepsy.com (Accessed February 20, 2019)
[11]
Funck-Brentano, C.; Szymezak, J.; Steichen, O.; Ducint, D.; Molimard, M.; Remones, V.; Azizi, M.; Gaussem, P. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch. Cardiovasc. Dis., 2013, 106(12), 661-671.
[http://dx.doi.org/10.1016/j.acvd.2013.09.002] [PMID: 24246616]
[12]
French, J.; Edrich, P.; Cramer, J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res., 2001, 47(1-2), 77-90.
[http://dx.doi.org/10.1016/S0920-1211(01)00296-0] [PMID: 11673023]
[13]
Giarratano, M.; Standley, K.; Benbadis, S.R. Clobazam for treatment of epilepsy. Expert Opin. Pharmacother., 2012, 13(2), 227-233.
[http://dx.doi.org/10.1517/14656566.2012.647686] [PMID: 22242724]
[14]
Ghiculescu, R.A. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust. Prescr., 2008, 31(2), 42.
[http://dx.doi.org/10.18773/austprescr.2008.025]
[15]
Giraud, C.; Tran, A.; Rey, E.; Vincent, J.; Tréluyer, J.M.; Pons, G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab. Dispos., 2004, 32(11), 1279-1286.
[http://dx.doi.org/10.1124/dmd.32.11.1279] [PMID: 15483195]
[16]
Hirsch, L.J.; Arif, H.; Buchsbaum, R.; Weintraub, D.; Lee, J.; Chang, J.T.; Resor, S.R., Jr; Bazil, C.W. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia, 2007, 48(7), 1351-1359.
[http://dx.doi.org/10.1111/j.1528-1167.2007.01043.x] [PMID: 17573925]
[17]
Ishizaki, T.; Horai, Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment. Pharmacol. Ther., 1999, 13(Suppl. 3), 27-36.
[http://dx.doi.org/10.1046/j.1365-2036.1999.00022.x] [PMID: 10491726]
[18]
Johannessen, S.I.; Landmark, C.J. Antiepileptic drug interactions - principles and clinical implications. Curr. Neuropharmacol., 2010, 8(3), 254-267.
[http://dx.doi.org/10.2174/157015910792246254] [PMID: 21358975]
[19]
Kang, J.S.; Lee, M.H. Overview of therapeutic drug monitoring. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.), 2009, 24(1), 1-10.
[http://dx.doi.org/10.3904/kjim.2009.24.1.1] [PMID: 19270474]
[20]
Levy, R.H.; Lane, E.A.; Guyot, M.; Brachet-Liermain, A.; Cenraud, B.; Loiseau, P. Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab. Dispos., 1983, 11(4), 286-292.
[PMID: 6137332]
[21]
Lynch, B.A.; Lambeng, N.; Nocka, K.; Kensel-Hammes, P.; Bajjalieh, S.M.; Matagne, A.; Fuks, B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 2004, 101(26), 9861-9866.
[http://dx.doi.org/10.1073/pnas.0308208101] [PMID: 15210974]
[22]
McColl, K.E.; Kennerley, P. Proton pump inhibitors--differences emerge in hepatic metabolism. Dig. Liver Dis., 2002, 34(7), 461-467.
[http://dx.doi.org/10.1016/S1590-8658(02)80102-5] [PMID: 12236477]
[23]
Montenegro, M.A.; Arif, H.; Nahm, E.A.; Resor, S.R., Jr; Hirsch, L.J. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin. Neuropharmacol., 2008, 31(6), 333-338.
[http://dx.doi.org/10.1097/WNF.0b013e31815cd960] [PMID: 19050410]
[24]
Naccarato, M.; Yoong, D.; Kovacs, C.; Gough, K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir. Ther. (Lond.), 2012, 17(3), 589-592.
[http://dx.doi.org/10.3851/IMP1953] [PMID: 22293514]
[25]
Nilsson, L.; Bergman, U.; Diwan, V.; Farahmand, B.Y.; Persson, P.G.; Tomson, T. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia, 2001, 42(5), 667-673.
[http://dx.doi.org/10.1046/j.1528-1157.2001.22000.x] [PMID: 11380576]
[26]
Parmeggiani, A.; Posar, A.; Sangiorgi, S.; Giovanardi-Rossi, P. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain Dev., 2004, 26(1), 63-66.
[http://dx.doi.org/10.1016/S0387-7604(03)00074-3] [PMID: 14729419]
[27]
Patsalos, P.N. The pharmacokinetic characteristics of levetiracetam. Methods Find. Exp. Clin. Pharmacol., 2003, 25(2), 123-129.
[http://dx.doi.org/10.1358/mf.2003.25.2.723686] [PMID: 12731458]
[28]
Patsalos, P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther., 2000, 85(2), 77-85.
[http://dx.doi.org/10.1016/S0163-7258(99)00052-2] [PMID: 10722121]
[29]
Patsalos, P.N.; Berry, D.J.; Bourgeois, B.F.; Cloyd, J.C.; Glauser, T.A.; Johannessen, S.I.; Leppik, I.E.; Tomson, T.; Perucca, E. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49(7), 1239-1276.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01561.x] [PMID: 18397299]
[30]
Perucca, E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol., 2006, 61(3), 246-255.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02529.x] [PMID: 16487217]
[31]
Pok, P.R.; Mauras, M.; De Saint Léger, M.N.; Kuhlmann, E.; Charpenel-Durat, C.; Navarette, C.; Duval, M.L.; De Meo, P. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate. Leg. Med. (Tokyo), 2010, 12(6), 300-304.
[http://dx.doi.org/10.1016/j.legalmed.2010.08.002] [PMID: 20870445]
[32]
Proença, P.; Teixeira, H.; Pinheiro, J.; Marques, E.P.; Vieira, D.N. Forensic intoxication with clobazam: HPLC/DAD/MSD analysis. Forensic Sci. Int., 2004, 143(2-3), 205-209.
[http://dx.doi.org/10.1016/j.forsciint.2004.03.029] [PMID: 15240045]
[33]
Radtke, R.A. Pharmacokinetics of levetiracetam. Epilepsia, 2001, 42(Suppl. 4), 24-27.
[http://dx.doi.org/10.1046/j.1528-1157.2001.0420s4024.x] [PMID: 11564121]
[34]
Sohn, D.R.; Kwon, J.T.; Kim, H.K.; Ishizaki, T. Dong-Ryul. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin. Pharmacol. Ther., 1997, 61(5), 574-582.
[http://dx.doi.org/10.1016/S0009-9236(97)90137-5] [PMID: 9164419]
[35]
Shah, N.M.; Hawwa, A.F.; Millership, J.S.; Collier, P.S.; Ho, P.; Tan, M.L.; Peake, D.; Tirupathi, S.; Bothwell, J.; Bailie, N.; Shepherd, C.; Craig, J.; McElnay, J.C. Adherence to antiepileptic medicines in children: a multiple-methods assessment involving dried blood spot sampling. Epilepsia, 2013, 54(6), 1020-1027.
[http://dx.doi.org/10.1111/epi.12126] [PMID: 23448146]
[36]
Tanaka, M.; Ohkubo, T.; Otani, K.; Suzuki, A.; Kaneko, S.; Sugawara, K.; Ryokawa, Y.; Hakusui, H.; Yamamori, S.; Ishizaki, T. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin. Pharmacol. Ther., 1997, 62(6), 619-628.
[http://dx.doi.org/10.1016/S0009-9236(97)90081-3] [PMID: 9433390]
[37]
Jochen, G.W. Theis.; Gideon, Koren.; Richard, Daneman.; Allan, L.; Sherwin.; Enrique, Menzano.; Miguel, Cortez.; Paul, Hwang. Interactions of clobazam with conventional antiepileptics in children. J. Child Neurol., 1997, 12, 208-221.
[38]
Walzer, M.; Bekersky, I.; Blum, R.A.; Tolbert, D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy, 2012, 32(4), 340-353.
[http://dx.doi.org/10.1002/j.1875-9114.2012.01028.x] [PMID: 22422635]
[39]
Yasuda, S.; Horai, Y.; Tomono, Y.; Nakai, H.; Yamato, C.; Manabe, K.; Kobayashi, K.; Chiba, K.; Ishizaki, T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin. Pharmacol. Ther., 1995, 58(2), 143-154.
[http://dx.doi.org/10.1016/0009-9236(95)90192-2] [PMID: 7648764]
[40]
Zvyaga, T.; Chang, S.Y.; Chen, C.; Yang, Z.; Vuppugalla, R.; Hurley, J.; Thorndike, D.; Wagner, A.; Chimalakonda, A.; Rodrigues, A.D. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab. Dispos., 2012, 40(9), 1698-1711.
[http://dx.doi.org/10.1124/dmd.112.045575] [PMID: 22648560]

Rights & Permissions Print Cite
Article Metrics
40
2
© 2024 Bentham Science Publishers | Privacy Policy